Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

32.360
+0.8202.60%
Volume:43.23M
Turnover:1.39B
Market Cap:133.91B
PE:24.59
High:32.680
Open:31.300
Low:31.040
Close:31.540
52wk High:44.000
52wk Low:16.200
Shares:4.14B
HK Float Shares:4.14B
Volume Ratio:1.08
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.316
ROE:11.64%
ROA:6.88%
PB:2.50
PE(LYR):24.59
PS:5.42

Loading ...

CANBRIDGE-B Shares Surge Over 6% Following Announcement of Private Placement to WUXI BIO Subsidiary

Stock News
·
Feb 25

Wuxi Biologics (Cayman) Stock Slips 2.3% in Hong Kong

Dow Jones
·
Feb 24

Wuxi Biologics (Cayman) Stock Advances 1.3% in Hong Kong

Dow Jones
·
Feb 16

BUZZ-CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares

Reuters
·
Feb 16

CANBRIDGE-B Shares Surge Following Discounted Share Placement

Stock News
·
Feb 16

JPMorgan Raises WUXI BIO Target Price to HK$51 Following Strong Earnings Beat and Robust Order Pipeline

Stock News
·
Feb 13

Wuxi Biologics (Cayman) Stock Sheds 3.2% in Hong Kong

Dow Jones
·
Feb 13

Vertex posts FY2025 GAAP operating income of USD 4.17 billion

Reuters
·
Feb 13

Morgan Stanley Forecasts WuXi Biologics Shares to Rise in Next 45 Days, Raises Target Price to HK$50

Stock News
·
Feb 12

WUXI BIO Shares Surge Over 6% Again on Stronger-Than-Expected Second-Half Profit and Margin Expansion

Stock News
·
Feb 12

Wuxi Biologics (Cayman) Stock Rallies 3.4% in Hong Kong

Dow Jones
·
Feb 11

China stocks steady as metals rally counters consumer, AI losses

Reuters
·
Feb 11

BUZZ-WuXi Biologics climbs to 4-month high on robust earnings estimates

Reuters
·
Feb 11

BRIEF-Wuxi Biologics FY Revenue RMB21,790 Million

Reuters
·
Feb 11

WUXI BIO Issues Positive Profit Alert, Anticipates 46.3% Rise in Annual Shareholder Profit

Stock News
·
Feb 11

WuXi Biologics (Cayman) Inc. (Stock Code: 2269) Anticipates Notable Profits Growth for FY2025

Bulletin Express
·
Feb 11

WuXi Biologics (Cayman) Inc. (2269) Schedules Board Meeting to Review 2025 Annual Results

Bulletin Express
·
Feb 11

WuXi Biologics Board to Approve Annual Results

Reuters
·
Feb 11

Wuxi Biologics Expects 2025 Revenue to Rise 16.7% to RMB21.79 Billion

Reuters
·
Feb 11

WuXi Biologics -FY Profit Expected to Increase to RMB5,733 Mln

THOMSON REUTERS
·
Feb 11